Related Experiment Video
Updated: Aug 14, 2025
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory
Darshana Patil1, Dadasaheb Akolkar1, Rajnish Nagarkar2
1Department of Research and Innovation, Datar Cancer Genetics, Nasik, India.
Purpose:
The selection of safe and efficacious anticancer regimens for treatment of patients with broadly refractory metastatic cancers remains a clinical challenge. Such patients are often fatigued by toxicities of prior failed treatments and may have no further viable standard of care treatment options. Liquid Biopsy-based multi-analyte profiling in peripheral blood can identify a majority of drug targets that can guide the selection of efficacious combination regimens.
Patients And Methods:
LIQUID IMPACT was a pilot clinical study where patients with advanced refractory cancers received combination anticancer treatment regimens based on multi-analyte liquid biopsy (MLB) profiling of circulating tumor biomarkers; this study design was based on the findings of prior feasibility analysis to determine the abundance of targetable variants in blood specimens from 1299 real-world cases of advanced refractory cancers.
Results:
Among the 29 patients in the intent to treat (ITT) cohort of the trial, 26 were finally evaluable as per study criteria out of whom 12 patients showed Partial Response (PR) indicating an Objective Response Rate (ORR) of 46.2% and 11 patients showed Stable Disease (SD) indicating the Disease Control Rate (DCR) to be 88.5%. The median Progression-Free Survival (mPFS) and median Overall Survival (mOS) were 4.3 months (95% CI: 3.0 - 5.6 months) and 8.8 months (95% CI: 7.0 - 10.7 months), respectively. Toxicities were manageable and there were no treatment-related deaths.
Conclusion:
The study findings suggest that MLB could be used to assist treatment selection in heavily pretreated patients with advanced refractory cancers.
Insights
Multi-analyte liquid biopsy (MLB) profiling guides cancer treatment selection for refractory metastatic cancers. This pilot study showed a 46.2% objective response rate and manageable toxicities, suggesting MLB
Area of Science:
- Oncology
- Translational Medicine
- Biomarker Discovery
Background:
- Selecting effective treatments for refractory metastatic cancers is challenging.
- Patients often face treatment fatigue and limited options.
- Liquid biopsy offers a potential solution for identifying drug targets.
Purpose of the Study:
- To evaluate the efficacy of combination anticancer regimens guided by multi-analyte liquid biopsy (MLB) profiling.
- To assess the feasibility of using MLB in heavily pretreated patients with advanced refractory cancers.
Main Methods:
- The LIQUID IMPACT pilot study enrolled patients with advanced refractory cancers.
- Treatment regimens were based on MLB profiling of circulating tumor biomarkers.
- Feasibility analysis of 1299 real-world cases informed study design.
Main Results:
- Among 26 evaluable patients, the Objective Response Rate (ORR) was 46.2% (12 Partial Responses).
- The Disease Control Rate (DCR) was 88.5% (11 Stable Disease).
- Median Progression-Free Survival (mPFS) was 4.3 months; median Overall Survival (mOS) was 8.8 months. Toxicities were manageable.
Conclusions:
- MLB profiling can assist in selecting treatments for heavily pretreated patients with advanced refractory cancers.
- This approach shows promise in improving outcomes for challenging cancer cases.
More Related Videos
05:26A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
Published on: September 16, 2022
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
